Vestfold Hospital Trust
Tønsberg, Norway
NCT Number: NCT03695081
Medication errors represent the most common cause of patient injury and one of the most frequently reported health related deviation in Norway. The addition of a dedicated clinical pharmacist throughout the hip fracture patient pathway (patient pathway pharmacist) is believed to improve patient safety and ensure optimal drug-related patient care. The pharmacist will perform medication reconciliation at admission to hospital, medication review after surgery and assist physicians with discharge summary. Six weeks after discharge the patient pathway pharmacist will perform a second drug reconciliation and medication review. This study will assess the pharmacists' place and specific tasks in the patient pathway, describe areas where the pharmacist contribute to increased quality of care and assess the benefits and/or disadvantages experienced with introducing a patient pathway pharmacist. The estimated number of patients included is 60. Current practice will be determined by investigating the last 50 patients' medical record and a questionnaire to health care professionals involved in treatment of hip fracture patients. Data from medication reconciliation and drug review will be collected and compared to current practice. After the inclusion period, focus group surveys and/or semi-structured interviews will be executed to describe the perceived improvement in the quality of care. Primary endpoints are: 1) Medication reconciliation score at admission 2) Number of inappropriate drugs for elderly 3) Discharge summary score 4) Discharge summaries following procedure. Secondary endpoints are readmissions and mortality after 30 and 90 days. Qualitative endpoints: 1) Health care professionals experience of current drug-related practice 2) Experienced advantages and disadvantages of a patient pathway pharmacist.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Tønsberg, Norway
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: At discharge (estimated five days after fracture/inclusion)
In the discharge summary, the section describing drugs is scored in accordance with the national patient safety program
Time frame: At hospital admission (estimated to be within 24 hours after fracture)
In the admission summary, the section describing drugs is scored. The score is adjusted from the discharge summary score to fit the admission note.
Time frame: At discharge (estimated five days after fracture/inclusion)
In the discharge summary, the section describing drugs should be in accordance with procedure.
Time frame: During hospitalisation, after surgery (estimated to be within five days after fracture/inclusion)
After surgery the medication review may reduce the number of inappropriate drugs (on the STOPP-list).
Time frame: 30 days after discharge
Patients who are readmitted to hospital is quantified
Time frame: 90 days after discharge
Patients who are readmitted to hospital is quantified
Time frame: 30 days after discharge
The number patients who dies is quantified
Time frame: 90 days after discharge
The number of patients who dies is quantified
Time frame: Prior to or during the early start of the intervention
A questionnaire will be distributed to all health care professionals involved in the treatment of hip fracture patients
Time frame: Within three months after last included patient
Focus groups or semi-structured interviews will be performed to assess the advantages and/or disadvantages of introducing a patient pathway pharmacist.
Sykehuset i Vestfold HF
Other
Patient Pathway Pharmacist: Drug Optimisation for Hip Fracture Patients - Facilitating a Safe Patient Handover: a Descriptive Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02272972
Femoral Fractures, Fractures, Bone
Columbia, Missouri, United States
View Trial DetailsNCT01701414
Femoral Fractures, Femoral Neck Fractures
Providence, Rhode Island, United States
View Trial DetailsNCT06438640
Femoral Fractures, Femoral Neck Fractures
Gainesville, Florida, United States
View Trial DetailsNCT02425345
Arterial Occlusive Diseases, Arteriosclerosis
View Trial Details